Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: A case control study

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Lee, Ju Hyun ^a   Park, Seho ^a   Park, Hyung S ^a   Park, Byeong Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RELAPSE; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INFILTRATING DUCTAL CARCINOMA; INFILTRATING LOBULAR CARCINOMA; KOREA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVARY METASTASIS; OVERALL SURVIVAL; BREAST TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951251893     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-34     Document Type: Article

References (26)

1. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000, 88:2561-2569. 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X, 10861434.
2. Jeong J, . The Korean Breast Cancer Society Nationwide Korean Breast Cancer Data of 2004 Using Breast Canser Registration Program. J Breast Cancer 2006, 9:151-161. The Korean Breast Cancer Society.
3. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008, 26:3006-3014. 10.1200/JCO.2007.14.9336, 18458044.
4. Mate TP, Carter D, Fischer DB, Hartman PV, McKhann C, Merino M, Prosnitz LR, Weissberg JB. A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer 1986, 58:1995-2002. 10.1002/1097-0142(19861101)58:9<1995::AID-CNCR2820580907>3.0.CO;2-1, 3019514.
5. Lester SC, Cotran RS. The breast. Robbins Pathologic Basis of Disease 1999, 1093-1119. Philadelphia: W.B. Saunders Company, Cotran RS, Kumar V, Collins T, 6.
6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189.
7. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6:R149-156. 10.1186/bcr767, 400666, 15084238.
8. Ministry of Health and Wellfare. Republic of Korea Cancer incidence in Korea 1999-2001 2005, Gwacheon, Korea: Ministry of Health and Wellfare, Ministry of Health and Wellfare. Republic of Korea.
9. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23:41-48. 10.1200/JCO.2005.03.111, 15625359.
10. Ko SS. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008, 98:318-323. 10.1002/jso.21110, 18623175.
11. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP. A comparative analysis of lobular and ductal carcinoma of the breast: Presentation, treatment, and outcomes. J Am Coll Surg 1998, 186:416-422. 10.1016/S1072-7515(98)00051-9, 9544955.
12. MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F, Coindre JM. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 1997, 10:769-776.
13. Poen JC, Tran L, Juillard G, Selch MT, Giuliano A, Silverstein M, Fingerhut A, Lewinsky B, Parker RG. Conservation therapy for invasive lobular carcinoma of the breast. Cancer 1992, 69:2789-2795. 10.1002/1097-0142(19920601)69:11<2789::AID-CNCR2820691126>3.0.CO;2-J, 1571910.
14. Soslow RA, Carlson DL, Horenstein MG, Osborne MP. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat 2000, 61:161-170. 10.1023/A:1006479113769, 10942102.
15. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW, Stewart HJ. Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg 1983, 70:513-516. 10.1002/bjs.1800700902, 6311313.
16. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW. Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. Br J Cancer 1989, 60:605-609. 2247102, 2803932.
17. Rosen PP. Rosen's breast pathology 2009, Philaddelpia; Lippincott Williams & Wilkins, a Wolters Kluwer business, 3.
18. Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 2005, 242:281-289. 10.1097/01.sla.0000171306.74366.22, 1357735, 16041220.
19. Harake MD, Maxwell AJ, Sukumar SA. Primary and metastatic lobular carcinoma of the breast. Clin Radiol 2001, 56:621-630. 10.1053/crad.2001.0766, 11467864.
20. Winston CB, Hadar O, Teitcher JB, Caravelli JF, Sklarin NT, Panicek DM, Liberman L. Metastatic lobular carcinoma of the breast: patterns of spread in the chest, abdomen, and pelvis on CT. AJR Am J Roentgenol 2000, 175:795-800.
21. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77:113-120. 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8, 8630916.
22. Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000, 114:190-196. 10.1309/CPUX-KWEH-7B26-YE19, 10941333.
23. Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 1991, 115:507-510.
24. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004, 291:1972-1977. 10.1001/jama.291.16.1972, 15113815.
25. Egervari K, Szollosi Z, Nemes Z. Immunohistochemical antibodies in breast cancer HER2 diagnostics. Tumor Biol 2008, 29:18-27.
26. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37:1217-1226. 10.1016/j.humpath.2006.04.015, 16938528.